NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's Copaxone reduced the risk of patients developing multiple sclerosis after they showed an initial sign of the central nervous system ...
In the late 1960s, three Weizmann Institute of Science researchers developed several protein-like molecules, called copolymers, that they believed would produce a disease similar to multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results